What's in Marc Sakwa, MD's pipeline?

Marc Sakwa, MD has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Marc Sakwa, MD's portfolio?

Top competitors by shared drug class: Dr. F. Köhler Chemie GmbH, Lourdes Montero Cruces, RenJi Hospital, Rigshospitalet, Denmark.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/marc-sakwa-md.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Marc Sakwa, MD — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Marc Sakwa, MD pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Custodiol HTK	Custodiol HTK	phase 3	Organ preservation solution		Transplantation

Therapeutic area mix

Transplantation · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Dr. F. Köhler Chemie GmbH · 1 shared drug class
Lourdes Montero Cruces · 1 shared drug class
RenJi Hospital · 1 shared drug class
Rigshospitalet, Denmark · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Marc Sakwa, MD:

Cite this brief

Drug Landscape (2026). Marc Sakwa, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/marc-sakwa-md. Accessed 2026-05-18.